CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$46.41 USD
-1.81 (-3.75%)
Updated Aug 14, 2024 03:59 PM ET
After-Market: $46.50 +0.09 (0.19%) 7:48 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
CRISPR Therapeutics AG [CRSP]
Reports for Purchase
Showing records 181 - 200 ( 221 total )
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Scientific Presentations Highlight Various Allogeneic CAR Constructs
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
New Trial Posted Last Night on Clinicaltrials.gov for Solid Tumor Therapy
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Updated Model with $105 PT on the Heels of EHA Data
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
CRISPR Cuts Away Troubling Inherited Hemoglobin Diseases
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
EHA Presentation on a Third Beta-thal Patient Treated with Crispr-Cas9. And There Is AACR.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
See Our Highlights from AACR II (June 22-24, 2020) Meeting Abstracts
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
1Q20: Four Programs in the Clinic. IND Approved for the Fifth
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department